Lake Street Capital Issues Pessimistic Forecast for OptimizeRx (NASDAQ:OPRX) Stock Price

OptimizeRx (NASDAQ:OPRX – Get Free Report) had its price objective lowered by Lake Street Capital from $11.00 to $10.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Lake Street Capital‘s target price would indicate a potential upside of 36.24% from the stock’s previous close.

Other equities analysts also recently issued research reports about the company. Wall Street Zen downgraded OptimizeRx from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 20th. UBS Group set a $11.00 price target on OptimizeRx in a research report on Friday, August 14th. Citizens Jmp raised their price target on OptimizeRx from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research report on Friday, August 14th. Citigroup reissued a “market outperform” rating on shares of OptimizeRx in a research note on Tuesday, October 27th. Finally, Stifel Nicolaus lowered their target price on shares of OptimizeRx from $12.00 to $11.00 and set a “buy” rating for the company in a report on Thursday. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.21.

Read Our Latest Stock Report on OPRX

OptimizeRx Stock Down 17.2%

OPRX opened at $7.34 on Thursday. The company has a market capitalization of $138.29 million, a PE ratio of 29.36 and a beta of 1.20. The firm has a 50-day simple moving average of $8.43 and a two-hundred day simple moving average of $7.20. The company has a quick ratio of 5.58, a current ratio of 5.06 and a debt-to-equity ratio of 0.09. OptimizeRx has a 52 week low of $4.54 and a 52 week high of $15.59.

OptimizeRx (NASDAQ:OPRX – Get Free Report) last released its quarterly earnings data on Wednesday, November 11th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.16 by $0.04. The business had revenue of $21.61 million for the quarter, compared to the consensus estimate of $21.19 million. OptimizeRx had a return on equity of 9.58% and a net margin of 5.33%. Analysts forecast that OptimizeRx will post 0.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of OPRX. Marshall Wace LLP boosted its position in shares of OptimizeRx by 183.2% in the 3rd quarter. Marshall Wace LLP now owns 459,362 shares of the company’s stock worth $3,836,000 after purchasing an additional 297,176 shares in the last quarter. Tocqueville Asset Management L.P. acquired a new stake in OptimizeRx in the third quarter worth about $1,670,000. Royce & Associates LP boosted its holdings in OptimizeRx by 20.7% in the third quarter. Royce & Associates LP now owns 1,315,057 shares of the company’s stock worth $10,981,000 after acquiring an additional 225,659 shares in the last quarter. Corient Private Wealth LP purchased a new stake in shares of OptimizeRx during the second quarter worth about $77,000. Finally, AWM Investment Company Inc. purchased a new stake in shares of OptimizeRx during the second quarter worth about $1,375,000. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

(Get Free Report)

OptimizeRx is a healthcare technology company that connects life sciences companies with healthcare professionals and patients through digital communications. Its platform uses channels such as electronic health records and other clinical workflows to deliver relevant information at the point of care. The company’s services support programs for medication access and affordability, patient education and engagement, and communication between healthcare providers and life sciences organizations. OptimizeRx also provides tools intended to help life sciences companies reach clinicians and patients through digital channels.

Read More

Analyst Recommendations for OptimizeRx (NASDAQ:OPRX)

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.